CRP and COVID-19: Following adjustment for age, baseline CRP, ethnicity, steroid use, and COVID-19 variant, there was evidence that the effect of treatment with anti-IL-6 receptor monoclonal antibodies differs between males and females (p = 0.14), although this was not statistically significant.